

(19)



(11)

EP 3 873 524 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:

09.04.2025 Bulletin 2025/15

(45) Date of publication and mention of the grant of the patent:

26.02.2025 Bulletin 2025/09

(21) Application number: **19878291.4**

(22) Date of filing: **30.10.2019**

(51) International Patent Classification (IPC):

A61K 39/395^(2006.01) A61K 51/00^(2006.01)
A61P 35/00^(2006.01)

(52) Cooperative Patent Classification (CPC):

A61P 35/02; A61K 9/0019; A61K 47/68035;
A61K 47/6849; C07K 16/2866; A61K 31/5513;
A61K 2039/505; A61K 2039/545; C07K 2317/92

(86) International application number:

PCT/US2019/058824

(87) International publication number:

WO 2020/092533 (07.05.2020 Gazette 2020/19)

(54) **METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES**

BEHANDLUNGSVERFAHREN UNTER VERWENDUNG VON ANTI-CD123-IMMUNOKONJUGATEN

PROCÉDÉS DE TRAITEMENT FAISANT APPEL À DES IMMUNOCONJUGUÉS ANTI-CD123

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

Designated Extension States:

BA ME

Designated Validation States:

KH MA MD TN

(30) Priority: **30.10.2018 US 201862752832 P**

12.06.2019 US 201962860565 P

31.07.2019 US 201962881137 P

(43) Date of publication of application:

08.09.2021 Bulletin 2021/36

(60) Divisional application:

25159743.1

(73) Proprietor: **ImmunoGen, Inc.**

North Chicago, IL 60064 (US)

(72) Inventors:

- **ZWEIDLER-MCKAY, Patrick**
Lincoln, Massachusetts 01773 (US)

- **CULM-MERDEK, Kerry**
Natick, Massachusetts 01760 (US)

- **SLOSS, Callum**

Wakefield, Massachusetts 01880 (US)

- **ROMANELLI, Angela**

Manchester-by-the-Sea, Massachusetts 01944 (US)

(74) Representative: **Simmons & Simmons LLP**

(Munich) et al

Lehel Carré

Gewürzmühlstraße 11

80538 Munich (DE)

(56) References cited:

WO-A2-2018/098258 US-A1- 2017 152 321

US-A1- 2017 152 321 US-A1- 2018 169 261

- **TOLCHER A.W.: "Antibody drug conjugates:**

lessons from 20 years of clinical experience",

ANNALS OF ONCOLOGY, vol. 27, no. 12, 1

December 2016 (2016-12-01), pages 2168 - 2172,

XP093147201, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw424

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 873 524 B8

- **DAVER NAVAL G ET AL: "A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 27, XP086593652, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-112955**
- **TOLCHER A.W.: "Antibody drug conjugates: lessons from 20 years of clinical experience", ANNALS OF ONCOLOGY, vol. 27, no. 12, 1 December 2016 (2016-12-01), pages 2168 - 2172, XP093147201, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw424**
- **DAVER NAVAL G ET AL: "A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 27, XP086593652, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-112955**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification